359 related articles for article (PubMed ID: 30735816)
21. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
22. Impact of KRAS
Caballé-Perez E; Hernández-Pedro N; Ramos-Ramírez M; Barrios-Bernal P; Romero-Núñez E; Lucio-Lozada J; Ávila-Ríos S; Reyes-Terán G; Cardona AF; Arrieta O
Clin Transl Oncol; 2024 Apr; 26(4):836-850. PubMed ID: 37490263
[TBL] [Abstract][Full Text] [Related]
23. The KRAS
Hallin J; Engstrom LD; Hargis L; Calinisan A; Aranda R; Briere DM; Sudhakar N; Bowcut V; Baer BR; Ballard JA; Burkard MR; Fell JB; Fischer JP; Vigers GP; Xue Y; Gatto S; Fernandez-Banet J; Pavlicek A; Velastagui K; Chao RC; Barton J; Pierobon M; Baldelli E; Patricoin EF; Cassidy DP; Marx MA; Rybkin II; Johnson ML; Ou SI; Lito P; Papadopoulos KP; Jänne PA; Olson P; Christensen JG
Cancer Discov; 2020 Jan; 10(1):54-71. PubMed ID: 31658955
[TBL] [Abstract][Full Text] [Related]
24. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
[TBL] [Abstract][Full Text] [Related]
25. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
Esteban-Burgos L; Wang H; Nieto P; Zheng J; Blanco-Aparicio C; Varela C; Gómez-López G; Fernández-García F; Sanclemente M; Guerra C; Drosten M; Galán J; Caleiras E; Martínez-Torrecuadrada J; Fajas L; Peng SB; Santamaría D; Musteanu M; Barbacid M
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24415-24426. PubMed ID: 32913049
[TBL] [Abstract][Full Text] [Related]
26. Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.
Boiarsky D; Lydon CA; Chambers ES; Sholl LM; Nishino M; Skoulidis F; Heymach JV; Luo J; Awad MA; Janne PA; Van Allen EM; Barbie DA; Vokes NI
Ann Oncol; 2023 Jul; 34(7):589-604. PubMed ID: 37121400
[TBL] [Abstract][Full Text] [Related]
27. Deregulated lncRNA expression profile in the mouse lung adenocarcinomas with KRAS-G12D mutation and P53 knockout.
Zhang M; Jiang N; Cui R; Du S; Ou H; Chen T; Ge R; Ma D; Zhang J
J Cell Mol Med; 2019 Oct; 23(10):6978-6988. PubMed ID: 31410985
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.
Chaft JE; Litvak A; Arcila ME; Patel P; D'Angelo SP; Krug LM; Rusch V; Mattson A; Coeshott C; Park B; Apelian DM; Kris MG; Azzoli CG
Clin Lung Cancer; 2014 Nov; 15(6):405-10. PubMed ID: 25044103
[TBL] [Abstract][Full Text] [Related]
29. RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma.
East P; Kelly GP; Biswas D; Marani M; Hancock DC; Creasy T; Sachsenmeier K; Swanton C; ; Downward J; de Carné Trécesson S
Nat Commun; 2022 Sep; 13(1):5632. PubMed ID: 36163168
[TBL] [Abstract][Full Text] [Related]
30. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
Aisner DL; Sholl LM; Berry LD; Rossi MR; Chen H; Fujimoto J; Moreira AL; Ramalingam SS; Villaruz LC; Otterson GA; Haura E; Politi K; Glisson B; Cetnar J; Garon EB; Schiller J; Waqar SN; Sequist LV; Brahmer J; Shyr Y; Kugler K; Wistuba II; Johnson BE; Minna JD; Kris MG; Bunn PA; Kwiatkowski DJ;
Clin Cancer Res; 2018 Mar; 24(5):1038-1047. PubMed ID: 29217530
[No Abstract] [Full Text] [Related]
31. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.
Ruiz-Cordero R; Ma J; Khanna A; Lyons G; Rinsurongkawong W; Bassett R; Guo M; Routbort MJ; Zhang J; Skoulidis F; Heymach J; Roarty EB; Tang Z; Medeiros LJ; Patel KP; Luthra R; Roy-Chowdhuri S
BMC Cancer; 2020 Jan; 20(1):83. PubMed ID: 32005111
[TBL] [Abstract][Full Text] [Related]
32. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.
Riely GJ; Johnson ML; Medina C; Rizvi NA; Miller VA; Kris MG; Pietanza MC; Azzoli CG; Krug LM; Pao W; Ginsberg MS
J Thorac Oncol; 2011 Aug; 6(8):1435-7. PubMed ID: 21847063
[TBL] [Abstract][Full Text] [Related]
33. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
Mack PC; Klein MI; Ayers KL; Zhou X; Guin S; Fink M; Rossi M; Ai-Kateb H; O'Connell T; Hantash FM; Oh WK; Newman S; Schadt EE; Chen R; Hirsch FR
Oncologist; 2022 Jun; 27(6):476-486. PubMed ID: 35298662
[TBL] [Abstract][Full Text] [Related]
34. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
35.
Jones GD; Caso R; Tan KS; Mastrogiacomo B; Sanchez-Vega F; Liu Y; Connolly JG; Murciano-Goroff YR; Bott MJ; Adusumilli PS; Molena D; Rocco G; Rusch VW; Sihag S; Misale S; Yaeger R; Drilon A; Arbour KC; Riely GJ; Rosen N; Lito P; Zhang H; Lyden DC; Rudin CM; Jones DR; Li BT; Isbell JM
Clin Cancer Res; 2021 May; 27(9):2604-2612. PubMed ID: 33593884
[TBL] [Abstract][Full Text] [Related]
36. Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma.
Liu K; Guo J; Liu K; Fan P; Zeng Y; Xu C; Zhong J; Li Q; Zhou Y
EBioMedicine; 2018 Oct; 36():196-208. PubMed ID: 30268834
[TBL] [Abstract][Full Text] [Related]
37. FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.
Elangovan IM; Vaz M; Tamatam CR; Potteti HR; Reddy NM; Reddy SP
Am J Respir Cell Mol Biol; 2018 May; 58(5):625-635. PubMed ID: 29112457
[TBL] [Abstract][Full Text] [Related]
38. Comparison of CT radiogenomic and clinical characteristics between EGFR and KRAS mutations in lung adenocarcinomas.
Lv J; Zhang H; Ma J; Ma Y; Gao G; Song Z; Yang Y
Clin Radiol; 2018 Jun; 73(6):590.e1-590.e8. PubMed ID: 29454587
[TBL] [Abstract][Full Text] [Related]
39. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
40. Notch1 Deficiency Induces Tumor Cell Accumulation Inside the Bronchiolar Lumen and Increases TAZ Expression in an Autochthonous
Meder L; Florin A; Ozretić L; Nill M; Koker M; Meemboor S; Radtke F; Diehl L; Ullrich RT; Odenthal M; Büttner R; Heukamp LC
Pathol Oncol Res; 2021; 27():596522. PubMed ID: 34257546
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]